Autoantibodies to folate receptor during pregnancy and neural tube defect risk

Robert M. Cabrera, Gary M. Shaw, Johnathan L. Ballard, Suzan L. Carmichael, Wei Yang, Edward J. Lammer, Richard H. Finnell Autoantibodies to folate receptor during pregnancy and neural tube defect risk Journal of Reproductive Immunology, In Press, Corrected Proof, Available online 18 September 2008


Abstract
Periconceptional folic acid can reduce the occurrence of neural tube defects (NTDs) by up to 70%, and autoantibodies for folate receptors (FRs) have been observed in serum from women with a pregnancy complicated by an NTD. This population-based cohort
study has examined serum from pregnant mothers for autoantibodies to FRs, antibodies to bovine folate binding protein (FBP), and inhibition of folic acid binding to FR and FBP in association with NTD risk. The mid-gestational maternal serum specimens
used for this study were collected during the 15–18th week of pregnancy. Samples were obtained from the California Birth Defects Monitoring Program; 29 mothers had a pregnancy complicated by spina bifida and 76 mothers had unaffected children. The presence of IgG and IgM antibodies to human FR, bovine FBP, and inhibition of folic acid binding to FR and FBP was determined. Higher activity of IgM to FBP in cases verses controls was observed (P = 0.04). Higher activity of IgM and IgG autoantibodies to FR was observed (P < 0.001 and P = 0.04, respectively). Risk estimates at two standard deviations above average control antibody
concentrations were OR= 2.07 (CI = 1.02, 4.06) for anti-FBP IgM, OR= 2.15 (CI = 1.02, 4.69) for anti-FR IgG and OR= 3.19 (CI = 1.47, 6.92) for anti-FR IgM. These data support the hypothesis that high titers of antibodies and blocking of folic acid binding to FRs by maternal serum should be regarded as risk factors for NTDs.
© 2008 Elsevier Ireland Ltd. All rights reserved.

Keywords: Folate receptor; Autoantibodies; Pregnancy; Neural tube defects